May 31, 2023
Tag: Brain Cancer
September 3, 2022
News & Observer: Common lab molecule surprises researchers with potential cancer-fighting properties
June 17, 2020
SCI NC: Using genetics to root out cancer
January 13, 2020
Researchers find clues to drug resistance in medulloblastoma subtype
A study led by UNC Lineberger's Tim Gershon, MD, PhD, shows new evidence to explain how drug resistance develops in a major subtype of medulloblastoma.
October 23, 2019
Researchers identify possible approach to block medulloblastoma growth
UNC Lineberger researchers have identified a potential approach to stop the growth of medulloblastoma, the most common type of brain tumor in children.
August 7, 2019
Charles M. Perou, PhD: From studying one gene, to studying thousands in breast cancer
Before he set out to understand how tens of thousands of genes are behaving in breast cancer, Charles M. Perou, PhD, spent five years hunting one gene. That experience started his journey to becoming a world-renowned expert in genomics.
June 28, 2019
Grateful patient works with lab team to find cancer therapies
David Hesmer is a volunteer in a UNC Lineberger lab, helping to further the study of glioblastoma, something he knows a lot about: he was treated for glioblastoma at the N.C. Cancer Hospital.
January 2, 2019
KFSN-TV: Battling brain tumors with Optune
August 27, 2018
Stem cells show promise as drug delivery tool for childhood brain cancer
UNC Lineberger’s Shawn Hingtgen, PhD, and his collaborators showed they could shrink tumors in laboratory models of medulloblastoma, and extend life. The study, published in PLOS ONE, is a necessary step toward developing clinical trials that would see if the approach works for children.
February 1, 2017
Revolutionary approach for treating glioblastoma works with human cells
UNC Lineberger's Shawn Hingtgen, PhD, and colleagues, in laboratory studies, have converted human skin cells into stem cells that can hunt down and kill human brain cancer, an important step to moving the approach closer to a clinical trial.